O3-1-3 - Chemotherapy-Induced Neutropenia in Patients with Gynecologic Malignancy

Abstract

Background: Chemotherapy-induced neutropenia seemed to be a serious problem in cancer treatment. In this study, we investigated chemotherapy-induced neutropenia recently performed in patients with gynecologic malignancy.Methods: Between January 2009 and December 2011, we examined our reported chemotherapy-induced neutropenia using the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. We analyzed the incidence and clinical features of chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy.Results: During this period we administered over 1614 infusions (29 regimens) to 291 patients with gynecologic malignancy. Median age was 60 years (24-84). Neutropenia occurred in 147 (50.5%) patients over 378 (23.4%) chemotherapy cycles. Febrile neutropenia occurred in 20 (6.9%) patients over 25 (1.5%) cycles. FN occurred after cycle 1 in 14 (56%) cycles. There were two neutropenic-related death cases. Neutropenia was associated with elderly age (over age 70) (p = 0.0001), less than five previous chemotherapy cycle (p = 0.02), disseminated disease (p = 0.03), platinum-based regimens (p = 0.0001), taxan-containing regimens (p = 0.0001) and combined therapy (p = 0.0001). Febrile neutropenia was associated with poor performance status (p = 0.0001), no previous chemotherapy (p = 0.05), disseminated disease (p = 0.0001) and distant metastatic disease (p = 0.03). Both neutropenia and febrile neutropenia were not related with bone marrow metastases or previous radiotherapy.Conclusions: Estimating risk factor of febrile neutropenia such as performance status and progression of disease seemed to be important for safe management of chemotherapy-induced neutropenia in patients with gynecologic malignancy.